NEWS
Special Reports
All News
FDA Briefs
Oncology Icons
The Targeted Pulse
CONFERENCES
Conference Coverage
Conference Listing
Data Dialogue with the Oncology Brothers
MEDIA
All Videos
Case-Based Peer Perspectives
Evolving Paradigms in Oncology
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Pivotal Practice Views with the Oncology Brothers
Podcasts
Practice Playbook
Shorts
Video Series
Webinars
PUBLICATIONS
All Publications
Evolving Paradigms
Peers & Perspectives in Oncology
Targeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CE
Clinical Trials
Events
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE
Scout
My Account
Scout
NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE
BRAIN CANCER
BREAST CANCER
HER2 Breast Cancer
COMMUNITY ONCOLOGY PRACTICE
GENITOURINARY CANCERS
Bladder Cancer
Prostate Cancer
Renal Cell Carcinoma
GENOMIC TESTING
Liquid Biopsies
GI CANCERS
Pancreatic Cancer
Colorectal Cancer
Gastric Cancer
GIST
HCC
GYNECOLOGIC CANCERS
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
HEAD & NECK CANCERS
HEMATOLOGY
Bone Marrow & Stem Cell Transplant
IMMUNOTHERAPY
CAR T-Cell Therapy
LEUKEMIAS
AML
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
LUNG CANCER
MET-Targeted Therapy
Small Cell Lung Cancer
Biomarker-Driven Lung Cancer
EGFR+ Lung Cancer
LYMPHOMAS
DLBCL
Follicular Lymphoma
Mantle Cell Lymphoma
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
ONCOLOGY POLICY
SARCOMA
SKIN CANCERS
Melanoma
THYROID CANCERS
Choose Specialty
Spotlight -
Community Oncology Practice
|
Oncology Policy
|
Myeloma
|
CLL
|
Genomic Testing
|
GU Cancers
Advertisement
BCR-ABL1 TKIs in Relapsed/Refractory CML
EP. 1: CML as an Ideal Cancer for Targeted Therapy With TKI
June 24th 2019
EP. 2: BCR-ABL1-Targeted TKIs in Treatment of CML
June 24th 2019
EP. 3: Response Monitoring of Patients With CML Treated With TKIs
June 24th 2019
EP. 4: Importance of Compliance With TKIs in Treatment of CML
June 24th 2019
EP. 5: Resistance to Targeted-TKI Treatment in Patients With CML
June 24th 2019
EP. 6: Frontline Treatment for CML With BCR-ABL-Targeted TKIs
June 24th 2019
EP. 7: Role of Ponatinib in Treatment of R/R CML
June 24th 2019
EP. 8: Early Intervention With Ponatinib in Treatment of CML
June 24th 2019
EP. 9: Bosutinib Versus Ponatinib in R/R CML
June 24th 2019
EP. 10: Adverse Events of Second-Generation TKIs Used in Treating CML
June 24th 2019
EP. 11: Dose-Related Adverse Events With Ponatinib When Treating CML
June 24th 2019
EP. 12: Treatment-Free Remission & Toxicities of Discontinuing CML Therapy
June 24th 2019
EP. 13: Challenges in Management of Chronic Phase CML
June 24th 2019
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
Weighing Logistics and Time Savings of Subcutaneous Drug Delivery
4
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
5
Designing Clinical Trials for Real-World Access
